← Back to headlines
Apellis Pharmaceuticals Receives New 'Buy' Rating from Roth
Apellis Pharmaceuticals has received a new 'Buy' rating from Roth, based on positive prospects for its drug Syfovre.
13 Mar, 15:43 — 13 Mar, 15:43
Sources
Showing 1 of 1 sources
